FDA
-
-
-
-
-
-
-
Iovance receives Australia approval for melanoma therapy Amtagvi
-
-
-
-
-
-
-
Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
-
-
-
-
-
-
-
Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates
-
-
-
-
-
-
-
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Iovance Biotherapeutics to Present at Upcoming Conferences
-
-
-
-
-
-
-
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Scott+Scott Attorneys at Law LLP Continues to Remind Investors of The Ongoing Securities Action Against Iovance Biotherapeutics, Inc. (IOVA)
-
329,914 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

